Investors with a lot of money to spend have taken a bearish stance on Biogen BIIB. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The results were shared at the American College of Rheumatology ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other genomics stocks. Genomics is the study of genes and how they function. Many rapidly growing ...

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...

Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s Alzheimer’s drug Leqembi. The investment bank said it doesn ...

Experts say to think of collagen banking as a savings account for your skin. You add more to your reserve, so you'll have as much stockpiled as possible ready to draw upon when the body's natural ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

A slow launch for Alzheimer’s medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen’s shares down this year. Although it ...

Based in Cambridge, MA, Biogen Inc. is one of the world’s leading biotechnology companies, which focuses on developing innovative therapies for treating serious neurological and ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Monday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.8 ...